Clinical Trials Sponsored by BiondVax Pharmaceuticals ltd.

Total 4379 results

Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Idorsia Pharmaceuticals Ltd.

Completed

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

Insomnia Disorder

United States, Germany
AFT Pharmaceuticals, Ltd.

Completed

Maxigesic 325 Acute Dental Pain Study

Dental Pain

United States, New Zealand
Atlantic Pharmaceuticals Ltd

Completed

Phase 1 Food Effect Study for Alicaforsen Tablets

IBD

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Essential Hypertension (REDUCE-1)

Essential Hypertension

Israel, Serbia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

Tezosentan in Acute Heart Failure (VERITAS 1)

Acute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart Failure

United States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma (CONTROL)

Asthma

United States, Australia, Bulgaria, Germany, Hungary, Israel, Poland, Russian Federation, Serbia, Singapore, South Africa, Sweden, Ukraine
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

Healthy

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

Primary Insomnia

United Kingdom
Avraham Pharmaceuticals Ltd

Completed

A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment

Dementia | Mild Cognitive Impairment

Germany, Austria, Israel
AFT Pharmaceuticals, Ltd.

Withdrawn

Maxi-Analgesic Osteoarthritis (OA) Study

Osteoarthritis
Faron Pharmaceuticals Ltd

Completed

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

Acute Respiratory Distress Syndrome | Acute Lung Injury

United Kingdom
AFT Pharmaceuticals, Ltd.

Withdrawn

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain

Dental Pain

United States
Sauflon Pharmaceuticals Ltd

Completed

Clinical Performance of All-in-One Light Multi-purpose for Silicone Hydrogel Contact Lenses

Healthy

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs (Neu I)

Primary Insomnia

France
Targia Pharmaceuticals Ltd.
SoluBest Ltd.

Unknown

Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers

Migraine
Clarity Pharmaceuticals Ltd

Recruiting

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) (COMBAT)

Prostatic Neoplasms | Castration-Resistant

United States
Fochon Pharmaceuticals, Ltd.

Recruiting

Study of FCN-098 in Patients With Advanced Solid Tumor

Solid Tumor

China
Fochon Pharmaceuticals, Ltd.

Recruiting

A Study of FCN-338 in Patients With Chronic CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Clarity Pharmaceuticals Ltd

Recruiting

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Idorsia Pharmaceuticals Ltd.

Enrolling by invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)

Acute Myocardial Infarction

United States, Spain, Denmark, Canada, Norway, France, China, United Kingdom, Hungary, Switzerland, Germany, Netherlands, Israel, Finland, Belgium, Czechia, Lithuania, Serbia, Austria, Italy, Bulgaria, Estonia, Poland, Romania, Slovakia, ...
Idorsia Pharmaceuticals Ltd.

Active, not recruiting

A Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia

Nocturia | Insomnia Disorder

Spain, United States, Germany
Faron Pharmaceuticals Ltd

Completed

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

Cancer

Finland, United Kingdom, Netherlands, United States, France, Spain
Kiniksa Pharmaceuticals, Ltd.

Completed

KPL-301 for Subjects With Giant Cell Arteritis

Giant Cell Arteritis

United States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain
KalVista Pharmaceuticals, Ltd.

Terminated

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (KVD824-201)

Angioedema, Hereditary, Types I and II

United States, Czechia, Germany, Hungary, Italy, North Macedonia, United Kingdom, Australia, Bulgaria, Canada, France, New Zealand, Puerto Rico
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

Binge-Eating Disorder

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

Healthy Subjects

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

Bioequivalence Study of Different Aprocitentan Tablet Formulations

Healthy Subjects

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Acute Myocardial Infarction

Switzerland, Israel, Belgium
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Healthy

Germany
Kiniksa Pharmaceuticals, Ltd.

Completed

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

COVID

United States, Brazil, South Africa, Chile, Peru
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY)

Fabry Disease

United States, Spain, Belgium, Australia, Austria, Canada, Germany, Ireland, Italy, Netherlands, Norway, Poland, Switzerland, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Healthy Subjects

Germany
Faron Pharmaceuticals Ltd

Withdrawn

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (RENACOL)

Carcinoma, Renal Cell | Carcinoma Colon

Finland
Alembic Pharmaceuticals Ltd.

Completed

Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg

Bioequivalence

Canada
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Insomnia Disorder

United States, Korea, Republic of, Germany, Belgium, Bulgaria, Canada, Czechia, Finland, France, Hungary, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470

Healthy | Drug Drug Interaction

Czechia
Alembic Pharmaceuticals Ltd.

Completed

Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg

Bioequivalence

Canada
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom

3

Subscribe